Eledon Pharmaceuticals Inc. (ELDN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Eledon Pharmaceuticals In... (ELDN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.71

-0.18 (-4.63%)

At close: Jan 14, 2025, 3:59 PM

3.71

-0.13%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	1.49
Market Cap	221.93M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.73
PE Ratio (ttm)	5.09
Forward PE	n/a
Analyst	Buy

Ask	4.92
Volume	351,526
Avg. Volume (20D)	617,927
Open	3.92
Previous Close	3.89
Day's Range	3.68 - 4.00
52-Week Range	1.52 - 5.54
Beta	undefined

About ELDN

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical tri...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 17, 2014

Employees 20

Stock Exchange NASDAQ

Ticker Symbol ELDN

Website https://eledon.com

Analyst Forecast

According to 1 analyst ratings, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 330.69% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-11.41%

Eledon Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription

8 months ago · Source

-7.38%

Eledon Pharmaceuticals shares are trading lower after the company announced an $50 million oversubscribed private placement. The company announced clinical progress with tegoprubart in the prevention of transplant rejection.

News

2 months ago · seekingalpha.com

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, u...